Leiomyosarcoma, Liposarcoma, Myxofibrosarcoma (MFS), Pleomorphic Rhabdomyosarcoma, Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma of the Trunk and Extremities, Synovial Sarcomas, Undifferentiated Pleomorphic Sarcoma (UPS)
Conditions
Keywords
Soft tissue sarcoma, proton radiotherapy, x-ray radiotherapy, surgical complications
Brief summary
The purpose of the study is to investigate whether a personalized selection of patients with localized soft tissue sarcoma for preoperative proton radiation therapy can reduce long-term radiation side effects without increasing surgical complications or reducing the effectiveness of the treatment. Two radiation plans will be created for each patient-one for protons and one for photons-and through a national meeting, we will determine which type of radiation therapy each patient will receive. The radiation dose will be the same for both photons and protons. The primary endpoint is surgical complications 120 days after surgery. Secondary endpoints include overall survival, local recurrence-free survival, disease-free survival, side effects, and quality of life. Furthermore, the study will investigate biomarkers that may predict response to radiation therapy, including changes in the tumor's genetic material (DNA), measurement of various molecules in the bloodstream, and the tumor's appearance on MRI scans. The study will be conducted in Norway, with a planned inclusion of 110 patients.
Detailed description
The objective of the PROSARC-1 trial is to investigate whether a national personalized approach with proton beam therapy (PBT) to selected soft tissue sarcoma (STS) patients can reduce long-term toxicity without increasing surgical complications or compromising local control. PROSARC-1 is a single arm, open-label, multicenter phase II trial initiated at Department of Oncology, Oslo University Hospital (OUS). The main inclusion criterion is patients with newly diagnosed STS of the head, neck, extremity or trunk wall. The primary endpoint is major wound complications (MVC) occurring within the first 120 days after surgery. We expect to include 110 patients over three years and all patients will be followed for up to five years. All the sarcoma centers in Norway participate in the study: OUS; Haukeland University hospital (HUH); St Olavs Hospital (SOH) and the University Hospital of North-Norway (UNN). The indication for preoperative radiotherapy (RT) will be decided in the sarcoma multidisciplinary (MDT) meeting at each center. For included patients, one X-ray radiotherapy (XRT) and one PBT plan will be made for comparison. A weekly national sarcoma radiotherapy meeting will compare the plans and recommend XRT or PBT treatment based on a careful clinical evaluation, also considering thresholds based on the toxicity grade. The prescribed dose is standard 42.75 Gy in 15 fractions over 3 weeks for both XRT and PBT. The PROSARC-1 trial includes translational radiomic research, where we aim to elucidate underlying mechanisms related to radiotherapy effect. To facilitate future biomarker studies for personalized therapy we will collect excess tumor tissue, whole blood, plasma and serum.
Interventions
RADIATIONpreoperative
The radiotherapy will be delivered 2.85 Gy x 15 for both x-ray or proton radiotherapy. A comparative doseplan will decide if the patient will receive proton og x-ray radiotherapy.
OTHERQuality of life
Questionnaire
OTHERFunctional outcome
Questionnaire
Sponsors
Oslo University Hospital
Haukeland University Hospital
University Hospital of Northern Norway, Tromsø, Norway
St. Olavs Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18 years of age at the time of informed consent. 2. Histological diagnosis of STS, except rhabdomyosarcoma and Ewing sarcoma. Pleomorphic rhabdomyosarcomas are eligible. 3. Primary tumor localized in head, neck, extremity, girdle and/or trunk wall. 4. Measurable disease according to RECIST v1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. 6. Before patient registration, written informed consent must be given according to national and local regulations. 7. Ability to fill in patient questionnaires and comply with study procedures, including travelling to Bergen or Oslo for PBT.
Exclusion criteria
1. Locoregional or distant metastasis as assessed by CT and/or MRI at time of diagnosis. Patients with lung nodules \<10 mm of uncertain etiology may be included. 2. Prior or concurrent malignant disease whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible. Patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may be included. Patients with a history of prostate cancer, requiring continued support with luteinizing hormone releasing hormone (LHRH) agonists, with or without androgens, may be included. 3. Previous radiotherapy to the primary tumor region. 4. Patients with pacemakers and/or implanted defibrillators. 5. Administration of systemic cancer therapy (i.e. chemotherapy, targeted therapy or immune therapy) within 14 days prior to the first fraction of radiotherapy. 6. Patients not able to give an informed consent or comply with study regulations as deemed by study investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major surgical complications | 120 days from surgery | The criteria that define a major wound complication include the following: * Secondary operation(s) required for wound treatment (e.g. debridement, secondary closure procedures such as rotationplasty, vacuum-assisted closure (VAC), free flaps or skin grafts); * Readmission to hospital for wound care; * Invasive procedures required for wound care (drainage of hematoma, seroma or infected wound collection); * Deep wound packing required at any time (deep packing defined as packing deep to dermis in an area of dehisced wound) to an area of wound measuring at least 2 cm in length; * Prolonged dressing changes, including packing of the wound for greater than six weeks from wound breakdown; * Repeat surgery for revision of a split thickness skin graft or requirement for wet dressings for longer than four weeks. (It is permissible for a patient to protect a totally epithelialized skin graft with a dry dressing without declaring a major wound complication). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local recurrence-free survival | Up to five years after radiation therapy. | Local recurrence-free survival is measured from the date of start of study treatment until date of local relapse as evaluated using RECIST v1.1 or date of death of any cause, whichever occurs first |
| Disease-free survival | Up to five years after radiation therapy | is measured from the date of start of study treatment until date of progressive disease as evaluated using RECIST v1.1, date of disease recurrence (local relapse or distant metastasis) or date of death of any cause, whichever occurs first. |
| Overall survival | Up to five years after radiation therapy | Overall survival is measured from the date of start of study treatment until date of death of any cause. |
| Overall response rate, defined as partial or complete response using RECIST v1.1 | Up to five years after radiation therapy | Radiological response will be assessed using MRI and/or CT of the primary tumor. |
| Pathological response | Perioperative | pathological response assessed by: Percentage of residual viable tumor cells; Mitotic index; and percentages of the following components of the resected tumor mass: necrosis, hemorrhage, sclerosis, sclerohyalinosis, fibrohistiocytic reaction with hemosiderin. |
| Health-related quality of life | Up to five years after radiation therapy | Change from baseline in EORTC QLQ-C30 scores. |
| Functional outcome | Up to five years after radiation therapy | Changes from baseline in Musculoskeletal Tumor Society Rating Scale (MSTS) |
Countries
Norway
Contacts
CONTACTMartine Karlsen Ødegaard, Cancer Nurse
PRINCIPAL_INVESTIGATORIvar Hompland, MD, PhD
Oslo University Hospital
STUDY_DIRECTORKjetil Boye, MD, PhD
Oslo University Hospital
Outcome results
None listed